GLYCOMIMETICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.55 USD | -5.49% |
|
-13.89% | -34.32% |
| Mar. 27 | Transcript : GlycoMimetics, Inc., Q4 2023 Earnings Call, Mar 27, 2024 | |
| Mar. 27 | GlycoMimetics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 229.4 | 179.8 | 74.5 | 158.8 | 152 | 105.7 | - | - |
| Enterprise Value (EV) 1 | 229.4 | 179.8 | 74.5 | 158.8 | 152 | 105.7 | 105.7 | 105.7 |
| P/E ratio | -3.95 x | -3.36 x | -1.17 x | -3.4 x | -4.07 x | -2.64 x | -4.53 x | 5.74 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 17.7 x | 64.2 x | 2,118 x | 15,197 x | - | 3.68 x | 1.23 x |
| EV / Revenue | - | 17.7 x | 64.2 x | 2,118 x | 15,197 x | - | 3.68 x | 1.23 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | -4.4 x | -4.57 x | -1.3 x | -3.41 x | - | -2.86 x | -2.25 x | -2.35 x |
| FCF Yield | -22.7% | -21.9% | -77.2% | -29.3% | - | -35% | -44.5% | -42.6% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 43,360 | 47,829 | 51,739 | 52,424 | 64,393 | 64,450 | - | - |
| Reference price 2 | 5.290 | 3.760 | 1.440 | 3.030 | 2.360 | 1.550 | 1.550 | 1.550 |
| Announcement Date | 2/28/20 | 3/2/21 | 3/3/22 | 3/29/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 10.16 | 1.16 | 0.075 | 0.01 | - | 28.74 | 85.72 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -61.39 | -51.51 | -63.45 | -47.4 | -39.28 | -41.44 | -30.34 | 18.85 |
| Operating Margin | - | -506.83% | -5,469.57% | -63,204% | -392,750% | - | -105.58% | 21.99% |
| Earnings before Tax (EBT) 1 | -57.89 | -51.03 | -63.43 | -46.69 | -36.9 | -41.21 | -56.04 | -23.64 |
| Net income 1 | -57.89 | -51.03 | -63.43 | -46.69 | -36.9 | -40.64 | -29.97 | 18.97 |
| Net margin | - | -502.09% | -5,467.84% | -62,250.67% | -368,990% | - | -104.27% | 22.12% |
| EPS 2 | -1.340 | -1.120 | -1.230 | -0.8900 | -0.5800 | -0.5867 | -0.3425 | 0.2700 |
| Free Cash Flow 1 | -52.13 | -39.31 | -57.5 | -46.54 | - | -37 | -47 | -45 |
| FCF margin | - | -386.8% | -4,957.28% | -62,055.57% | - | - | -163.54% | -52.5% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/20 | 3/2/21 | 3/3/22 | 3/29/23 | 3/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.087 | 0.018 | - | 0.075 | - | - | - | - | - | 0.01 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -17.34 | -17.43 | -14.66 | -13.35 | -8.768 | -10.62 | -10.94 | -8.93 | -9.814 | -9.591 | -9.877 | -10.06 | -10.31 | -10.84 |
| Operating Margin | -19,927.59% | -96,811.11% | - | -17,804% | - | - | - | - | - | -95,910% | - | - | - | - |
| Earnings before Tax (EBT) | -17.33 | -17.42 | -14.65 | -13.27 | -8.524 | -10.24 | -10.36 | -8.259 | -9.203 | -9.079 | - | - | - | - |
| Net income 1 | -17.33 | -17.42 | -14.65 | -13.27 | -8.524 | -10.24 | -10.36 | -8.259 | -9.203 | -9.079 | -9.664 | -9.894 | -10.19 | -10.62 |
| Net margin | -19,921.84% | -96,788.89% | - | -17,689.33% | - | - | - | - | - | -90,790% | - | - | - | - |
| EPS 2 | -0.3400 | -0.3300 | -0.2800 | -0.2500 | -0.1600 | -0.1900 | -0.1700 | -0.1300 | -0.1400 | -0.1400 | -0.1450 | -0.1500 | -0.1400 | -0.1450 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/3/22 | 4/28/22 | 8/3/22 | 11/9/22 | 3/29/23 | 5/3/23 | 8/2/23 | 11/3/23 | 3/27/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -52.1 | -39.3 | -57.5 | -46.5 | - | -37 | -47 | -45 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.14 | 0.07 | 0.01 | 0.08 | - | 0.05 | 0.07 | - |
| Capex / Sales | - | 0.67% | 1.29% | 112.25% | - | - | 0.24% | - |
| Announcement Date | 2/28/20 | 3/2/21 | 3/3/22 | 3/29/23 | 3/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.64
USD
Average target price
7
USD
Spread / Average Target
+326.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.32% | 106M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- GLYC Stock
- Financials GlycoMimetics, Inc.
